EXTON, Pa., Aug. 23 Isolagen(TM), Inc.(Amex: ILE) today announced that it completed its previously announcedregistered direct offering of approximately 6.76 million shares of commonstock at a price of $2.04 per share to institutional investors for grossproceeds of approximately $13.8 million. The shares were offered under aneffective shelf registration statement previously filed with the Securitiesand Exchange Commission.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be any saleof these securities in any state or jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration or qualificationunder the securities laws of any such state or jurisdiction.
About Isolagen, Inc.
Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic companycommitted to developing and commercializing scientific advances and innovativetechnologies. The company's technology platform includes the IsolagenProcess(TM), a cell processing system for skin and tissue rejuvenation whichis currently in clinical development for a broad range of aesthetic andtherapeutic applications including wrinkles, acne scars, burns and periodontaldisease. Isolagen also commercializes a scientifically-advanced line ofskincare systems through its majority-owned subsidiary, Agera(R) Laboratories,Inc. For additional information, please visit www.isolagen.com.
SOURCE Isolagen(TM), Inc.